Skip to main content
Caplight Logo









Melio

Melio

Private
Santa Clara, CaliforniaHealthcare & Life Scienceshttps://melio.tech/

Last Round

Grant

Jan 14, 2025

Total Funding Raised

$10.7M

Company Overview

Melio is a biotechnology company developing a rapid, culture-free bloodborne pathogen testing platform that integrates proprietary assays, microfluidics, and machine learning to identify infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Medical AI, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

infectious disease diagnosticspathogen detectionrapid diagnosticsculture-free diagnosticsmedical AIantimicrobial resistanceAMRmicrofluidicsdiagnostic softwarebloodborne pathogen testingneonatal sepsispoint of care diagnosticsPOC diagnosticsclinical diagnosticsdigital health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Melio Comparables

Compare Melio with similar companies based on industry and business-model similarity.

Melio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HelixBind
84%
Vivid Dx
82%
Microbio
81%

Melio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 14, 2025
SeedJun 30, 2024

Key People

Founding team and executive leadership

Mridu Sinha

Co-Founder & CEO

Founding Team

Wendy Wong

Chief Product Officer

Executive Team

Melio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2025

    Grew 20% QoQ, from 30 to 36 employees.

  • May 11, 2025

    Grew 17% QoQ, from 30 to 35 employees.

Melio Filings

Explore SEC and related filing metadata, where available.

Melio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Melio's valuation, stock price, and market status.

Is Melio a public or private company?

Melio is a private company.

What is the current stock price of Melio?

Melio is a private company with no public stock price. No recent secondary market data is available.

How much is Melio worth (valuation)?

Valuation information for Melio is not publicly available.

Can I buy Melio stock?

Melio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Melio's last funding round?

Melio's most recent funding round was Grant on January 14, 2025.

Who are the main investors in Melio?

Key investors in Melio include Lexi Ventures, MIT Alumni Angels of Northern California, CARB-X, Catalytic Impact Foundation, Cove Fund.

Will Melio IPO soon?

No public IPO plans have been announced for Melio.

How can I track Melio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Melio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSanta Clara, California
Employee Range23
Year FoundedN/A
Last FundingJan 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?